Rick is an active board member, investor, and entrepreneur in ophthalmic pharmaceutical and medical device companies. He has served as Chairman and Founder of TearClear since early 2016. TearClear is a specialty ophthalmic pharmaceutical company with a family of products developed to deliver preservative-free drugs from preserved multi-dose bottles. Rick is a board member of Lentechs, a company developing a disruptive presbyopic and toric lens.
Rick has been CEO of Amydis Diagnostics, a biotech developing a diagnostic for Alzheimer’s through the retina. He was CEO of RxSight/Calhoun Vision, a company developing a revolutionary light adjustable intraocular lens. Previously he served as Executive Vice President at Bausch + Lomb. He was a board member of the Association of the Blind and Visually Impaired (ABVI) and a contributor to the Lions Club helping to raise money to treat pediatric cataracts.
Rick co-authored “The Merger Dividend,” published in Harvard Business Review. He has been featured in Bloomberg Businessweek, Chief Executive Magazine, and Pharmaceutical Executive. Rick holds a Bachelor’s degree from Boston University, and a Master of Management from McGill University.